secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-08-06T11:01:35+00:00
Accession:  0001534120-26-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics Q2 2026 net loss $36.4M; plans Phase 3 for abdakibart in HS in H1 2027
--------------------------------------------------------------------------------

- Net loss of $36.4M for Q2 2026, up from $20.8M in Q2 2025; diluted EPS of ($0.83) vs ($1.92).
- Cash, equivalents and investments of $472.2M as of June 30, 2026, expected to fund operations into 2029.
- R&D expenses $23.4M, including $10.0M development milestone for abdakibart; G&A $8.1M.
- Plans to initiate registrational Phase 3 program for abdakibart in hidradenitis suppurativa in H1 2027.
- Expanded pipeline with AVTX-010 (anti-IL-1β antibody); IND submission planned for H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/0001534120-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/avtx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer